ストックスクリーナーアプリを入手
30.98
0.19%
-0.03
Newamsterdam Pharma Company Nv (NAMS) 最新ニュース
Behavioral Patterns of NAMSW and Institutional Flows - Stock Traders Daily
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session - The Manila Times
A cholesterol pill's kidney and safety data head to a major heart meeting - Stock Titan
JPMorgan Chase & Co. Trims Stock Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Earnings Update: How does NewAmsterdam Pharma Company NV Equity Warrant compare to its peersGap Up & Long Hold Capital Preservation Plans - baoquankhu1.vn
Does NewAmsterdam Pharma Company NV have declining or rising EPSEarnings Beat & AI Forecasted Stock Moves - baoquankhu1.vn
NAMS SEC FilingsNewAmsterdam Pharma Company N.V 10-K, 10-Q, 8-K Forms - Stock Titan
(NAMS) Risk Channels and Responsive Allocation - Stock Traders Daily
Why is NewAmsterdam Pharma Company NV stock going downIPO Watch & Daily Oversold Bounce Ideas - baoquankhu1.vn
Truist initiates NewAmsterdam Pharma stock coverage with buy rating By Investing.com - Investing.com South Africa
Truist initiates NewAmsterdam Pharma stock coverage with buy rating - Investing.com
Published on: 2026-03-19 02:35:41 - baoquankhu1.vn
NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by Fcpm Iii Services B.V. - MarketBeat
NewAmsterdam Pharma Company N.V. $NAMS is Decheng Capital LLC's 5th Largest Position - MarketBeat
ArrowMark Colorado Holdings LLC Has $8.85 Million Holdings in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
NAMSW SEC FilingsNewAmsterdam Pha 10-K, 10-Q, 8-K Forms - Stock Titan
(NAMSW) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Gains Report: Why is NewAmsterdam Pharma Company NV stock going down2026 Spike Watch & Daily Technical Stock Forecast Reports - baoquankhu1.vn
NewAmsterdam Pharma (NASDAQ:NAMS) Director Sells $1,357,309.98 in Stock - MarketBeat
Insider Sell: Louis Lange Sells 44,619 Shares of NewAmsterdam Ph - GuruFocus
NewAmsterdam Pharma Director Sells Shares - TradingView
Director at NewAmsterdam Pharma (NAMS) sells 44,619 shares - Stock Titan
NewAmsterdam Pharma Company N.V. $NAMS Shares Acquired by Capital World Investors - MarketBeat
Warrant exercise and trust sale at NewAmsterdam Pharma (NASDAQ: NAMS) - Stock Titan
NewAmsterdam Pharma Company N.V. $NAMS Shares Bought by American Century Companies Inc. - MarketBeat
Louis Lange Sells 28,186 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
NewAmsterdam Pharma (NAMS) director exercises 44,619 warrants as trust sells 28,186 shares - Stock Titan
NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells $14,753,257.75 in Stock - MarketBeat
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells $3,165,350.10 in Stock - MarketBeat
Johannes Jacob Piete Kastelein Sells 101,409 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
(NAMS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Trend Report: Is NewAmsterdam Pharma Company NV Equity Warrant stock trending bullishMarket Performance Summary & Daily Technical Forecast Reports - baoquankhu1.vn
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma gives two new hires 10K options, 2,200 RSUs - Stock Titan
Proposed NAMS share sales reported via Form 144 (NAMS) - Stock Titan
Stock Recap: Is NewAmsterdam Pharma Company NV Equity Warrant stock trending bullish2025 Technical Patterns & Smart Money Movement Tracker - baoquankhu1.vn
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells $14,753,257.75 in Stock - Defense World
[144] NewAmsterdam Pharma Co N.V. SEC Filing - Stock Titan
NewAmsterdam Pharma Hits Day Low at $30.20 Amid Price Pressure - Markets Mojo
NewAmsterdam Pharma (NAMS) Stock Analysis: Exploring a 46.68% Potential Upside Amidst Strong Buy Ratings - DirectorsTalk Interviews
NewAmsterdam Pharma CEO Sells Over $14 Million in Shares - TradingView
NewAmsterdam Pharma (NAMS) CEO sells 443,707 shares after option exercise - Stock Titan
NewAmsterdam Pharma (NASDAQ: NAMS) files Form 144 to sell 443,707 shares - Stock Titan
NewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume IncreaseStill a Buy? - MarketBeat
NewAmsterdam Highlights Obicetrapib Progress in Investor Presentation - TipRanks
NewAmsterdam posts updated investor presentation highlighting obicetrapib efficacy, safety, IP and cash runway - TradingView
Obicetrapib data and AD signals in NewAmsterdam (NAMS) deck - Stock Titan
Handelsbanken Fonder AB Boosts Stake in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - Sahm
JPMorgan Chase & Co. Has $37.04 Million Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells 58,253 Shares of Stock - MarketBeat
NewAmsterdam Pharma (NAMS) CEO exercises options and sells 306,293 shares - Stock Titan
Liquidity Mapping Around (NAMS) Price Events - Stock Traders Daily
Rate Hike: Is NewAmsterdam Pharma Company NV stock overvalued or fairly pricedJuly 2025 Intraday Action & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
NAMS Stock Price and Chart — NASDAQ:NAMS - TradingView
NewAmsterdam Pharma (NAMS) Stock Analysis: A Biotech Play with 34.71% Upside Potential - DirectorsTalk Interviews
NAMSNewAmsterdam Pharma Company N.V Latest Stock News & Market Updates - Stock Titan
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells 45,481 Shares of Stock - MarketBeat
NewAmsterdam Pharma CSO Sells Shares - TradingView
NewAmsterdam Pharma (NAMS) CSO executes 45,481-share stock sale - Stock Titan
0.99%
3.03%
大文字化:
|
ボリューム (24 時間):